Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 26, 2026

Agora Data Achieves Industry First: Auto Loans Become Public, On-Chain Assets

View original at globenewswire.com
Agora Data Achieves Industry First: Auto Loans Become Public, On-Chain Assets ARLINGTON, Texas, March 26, 2026 (GLOBE NEWSWIRE) -- Agora Data, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Consumer auto loans can now exist as real-time, investable, blockchain-based real-world assets (RWAs), openly accessible to qualified market participants for the first time

    60% confidence

  • This achievement represents a structural transformation in auto finance. Auto loans are no longer confined to closed balance sheets traditionally held and managed inside financial institutions. Bringing them on-chain enables transparency, intelligence, and broader participation—while supporting smarter, more profitable consumer loan originations.

    60% confidence

  • Agora Data has consistently pushed the boundaries of innovation—launching the industry's first asset-pooled non-prime auto securitization in 2020 and the first to bring U.S. auto loans on-chain as tokenized real-world assets

    60% confidence

  • Public availability is a defining characteristic for blockchain-based capital markets. Agora's underwriting rigor, data discipline, and independent asset review capabilities support investor confidence. Auto loans are a compelling expansion of blockchain-enabled structured finance, grounded in real-world performance.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Agora Data Achieves Industry First: Auto Loans Become Public, On-Chain Assets — Source | Via News | Via News